<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299182</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0146</org_study_id>
    <nct_id>NCT00299182</nct_id>
  </id_info>
  <brief_title>Study of AMG 531 to Evaluate the Safety &amp; Efficacy in Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of AMG 531 that can&#xD;
      be given to treat thrombocytopenia (low platelet counts) in patients who have received&#xD;
      chemotherapy. Researchers will also look at the safety and effectiveness of AMG 531.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        1. To determine the clinical safety and tolerability of AMG 531 administered following&#xD;
           chemotherapy (R-HyperCVAD alternating with R-Ara-C/MTX) in patients with non-Hodgkin's&#xD;
           lymphoma.&#xD;
&#xD;
        2. To determine an optimal biologic dose (OBD) of AMG 531 in patients receiving R-HyperCVAD&#xD;
           and R-Ara-C/MTX.&#xD;
&#xD;
        3. To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and&#xD;
           platelet recovery following chemotherapy(chemo).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      1. To evaluate limited pharmacokinetics of AMG 531 administered by S.C. route with&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelets are cells that help make the blood clot. A decrease in platelets can cause&#xD;
      bleeding, which may prevent or delay a patient from receiving chemotherapy. R-HyperCVAD&#xD;
      (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and R-Ara-C/MTX&#xD;
      (rituximab, cytarabine, and methotrexate) are two chemotherapy regimens that are known to&#xD;
      increase the risk of lower platelet counts. Researchers want to find out if AMG 531 can lower&#xD;
      the risk and severity of this side effect. AMG 531 is a protein that stimulates platelet&#xD;
      production.&#xD;
&#xD;
      Before you can start treatment on this study, you will have what are called &quot;screening&#xD;
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in the&#xD;
      study. You will have a complete medical history and physical exam, including measurement of&#xD;
      vital signs (temperature, pulse, breathing rate, and blood pressure). You will have blood&#xD;
      collected (about 3 teaspoons) for routine tests. Radiologic tests such as CT or MRI scans&#xD;
      will be done as needed. Women who are able to have children must have a negative blood&#xD;
      pregnancy test.&#xD;
&#xD;
      You will also have about 1 teaspoon of blood drawn to see if the you have antibodies to the&#xD;
      study drug.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the toss of a coin) to one of four treatment groups. These 4 groups will also be split&#xD;
      into 2 separate subgroups (Arm A and Arm B). Participants in Arm A will either receive AMG&#xD;
      531 or placebo on Day -5 (5 days before chemotherapy starts) and Day 5 (5 days after&#xD;
      chemotherapy starts). A placebo is a substance that looks like the study drug but which has&#xD;
      no active ingredients. Every 2 out of 3 participants in Arm A will receive AMG 531. One out&#xD;
      of every 3 participants in Arm A will receive placebo.&#xD;
&#xD;
      Participants in Arm B will receive either AMG 531 or placebo on Day 5 and 7. Every 2 out of 3&#xD;
      participants in Arm B will receive AMG 531. One out of every 3 participants in Arm B will&#xD;
      receive placebo. The dose of AMG 531 that participants in both Arms A and B receive will&#xD;
      depend on when they enroll on the study. There are 3 different dose levels of AMG 531 being&#xD;
      studied. Each new group of participants will receive a higher dose than the previous group.&#xD;
&#xD;
      All participants will receive treatment with R-HyperCVAD and R-Ara-C/MTX chemotherapy by vein&#xD;
      in alternating cycles. In Cycle 1, all participants will receive R-HyperCVAD by itself. Each&#xD;
      cycle is 3 weeks long.&#xD;
&#xD;
      Three (3) weeks later, in Cycle 2, all participants will receive either AMG 531 or placebo&#xD;
      following R-Ara-C/MTX. The AMG 531/placebo will be given as an injection under the skin on&#xD;
      Days -5 and 5 (Arm A) or on Days 5 and 7 (Arm B). After 2 cycles of treatment, based on&#xD;
      response of the disease and tolerance to the treatment, all participants may be able to&#xD;
      receive up to 4 more cycles of chemotherapy followed by AMG 531. For Cycles 3-6, you will&#xD;
      follow the same schedule of therapy as in the first 2 cycles. The dose of AMG 531 may be&#xD;
      increased at one time point during the study based on the response of the platelet counts.&#xD;
&#xD;
      Blood (about 1 teaspoon) will be collected for the evaluation of anti-AMG 531 antibody status&#xD;
      at the end of Cycles 2 and 4. You will be taken off the study if your disease gets worse or&#xD;
      intolerable side effects occur. The number of blood tests drawn will depend on your clinical&#xD;
      condition. These samples (about 1 teaspoon each) will be taken at least 2 times a week and as&#xD;
      often as once a day during anticipated periods of low blood cell counts.&#xD;
&#xD;
      At the end of the study, you will have an interim medical history and physical exam,&#xD;
      including measurement of vital signs. You will have blood (about 1 teaspoon) drawn for&#xD;
      routine end-of-study analysis. Blood (about 1 teaspoon) will also be collected for the&#xD;
      evaluation of anti-AMG 531 antibody status.&#xD;
&#xD;
      This is an investigational study. R-HyperCVAD and R-Ara-C/MTX are commercially available&#xD;
      chemotherapy drugs. AMG 531 is not FDA approved or commercially available. At this time, AMG&#xD;
      531 is being used in this study for research purposes only. About 36 evaluable patients&#xD;
      (maximum of 50 patients) will take part in this study. All will be enrolled at University of&#xD;
      Texas (UT) M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet (PLT) Nadir</measure>
    <time_frame>Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)</time_frame>
    <description>Blood counts were performed at least two times a week and when clinically indicated during the study and daily when PLT count is &lt; 50K/μL until recovery (two consecutive counts showing upward trend). The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days Platelets Count of &lt; 100K/μL</measure>
    <time_frame>Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)</time_frame>
    <description>The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy&#xD;
Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 531</intervention_name>
    <description>Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <other_name>Romiplostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, &amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <other_name>AD</other_name>
    <other_name>Hydroxydaunomycin hydrocholoride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 &amp; 6.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 &amp; 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 &amp; 4 for patients &gt; 60 years and for patients with serum creatinine &gt; 1.5 mg/dL; Cycles 2,4,&amp; 6.</description>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.</description>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of previously untreated aggressive non-Hodgkin's lymphoma,&#xD;
             including patients with mantle cell lymphoma, who will be or are receiving treatment&#xD;
             with R-HyperCVAD and R-Ara-C/MTX. Patients in whom Rituximab is not used, due to&#xD;
             contraindication, will be eligible. Patients whose therapy was switched to&#xD;
             (R)Hyper-CVAD after initial treatment with (R)CHOP, because of aggressive disease will&#xD;
             also be eligible for the study.&#xD;
&#xD;
          2. Patients age &gt;/= 18 years.&#xD;
&#xD;
          3. Karnofsky Performance Scale &gt;/= 70.&#xD;
&#xD;
          4. Adequate hematologic (ANC &gt;/= 1000/mm(3), platelet count &gt;/= 100,000/mm(3) and Hgb &gt;/=&#xD;
             8gm/dL), renal (serum creatinine &lt; 2mg/dL), and hepatic functions (total bilirubin &lt;/=&#xD;
             2 times, serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate&#xD;
             transaminase (SGOT) &lt;/= 3 times the upper limit of the respective normal range).&#xD;
&#xD;
          5. Patients (male and female) with childbearing potential (defined as not post-menopausal&#xD;
             for 12 months or no previous surgical sterilization) must use adequate birth control.&#xD;
&#xD;
          6. Institutional Review Board (IRB)-approved signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. History of Central Nervous System (CNS) involvement.&#xD;
&#xD;
          3. Co-morbid medical or psychiatric illnesses that preclude treatment with intense dose&#xD;
             chemotherapy.&#xD;
&#xD;
          4. Patients with history of deep vein thrombosis (DVT) or pulmonary embolus.&#xD;
&#xD;
          5. History of any platelet disorders including Idiopathic thrombocytopenic purpura (ITP),&#xD;
             Thrombotic thrombocytopenic purpura (TTP) or bleeding disorders.&#xD;
&#xD;
          6. Prior surgery or Radiation Therapy (RT) within 2 weeks of study entry.&#xD;
&#xD;
          7. Patients with significant cardiac disease (New York Heart Association (NYHA) Class III&#xD;
             or IV), dysrrhythmia, or recent history of myocardial ischemia (MI) or ischemia,&#xD;
             transient ischemic attack or cerebrovascular accident (CVA) within the previous 6&#xD;
             months of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>AMG 531</keyword>
  <keyword>Romiplostim</keyword>
  <keyword>Placebo</keyword>
  <keyword>R-HyperCVAD</keyword>
  <keyword>R-Ara-C/MTX</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Decadron</keyword>
  <keyword>Neosar</keyword>
  <keyword>AD</keyword>
  <keyword>Hydroxydaunomycin hydrocholoride</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 2, 2006 to February 1, 2010. All recruitment done at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>The protocol is designed to combine the placebo of Arm A and Arm B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P2">
          <title>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P3">
          <title>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Arm A &amp; Arm B) With Chemotherapy</title>
          <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy&#xD;
Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P5">
          <title>1 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P6">
          <title>3 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="P7">
          <title>10 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemotherapy Changed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 41 participants, 36 received treatment with the study drug as per protocol and were evaluable for response and toxicity; 5 participants received only one dose and were evaluable for toxicity only.</population>
      <group_list>
        <group group_id="B1">
          <title>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B2">
          <title>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B3">
          <title>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Arm A &amp; Arm B) With Chemotherapy</title>
          <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy&#xD;
Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B5">
          <title>1 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B6">
          <title>3 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B7">
          <title>10 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="18" upper_limit="61"/>
                    <measurement group_id="B2" value="58" lower_limit="40" upper_limit="73"/>
                    <measurement group_id="B3" value="59" lower_limit="54" upper_limit="71"/>
                    <measurement group_id="B4" value="56" lower_limit="28" upper_limit="73"/>
                    <measurement group_id="B5" value="51" lower_limit="33" upper_limit="61"/>
                    <measurement group_id="B6" value="57" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B7" value="56" lower_limit="53" upper_limit="60"/>
                    <measurement group_id="B8" value="56" lower_limit="18" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet (PLT) Nadir</title>
        <description>Blood counts were performed at least two times a week and when clinically indicated during the study and daily when PLT count is &lt; 50K/μL until recovery (two consecutive counts showing upward trend). The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
        <time_frame>Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A 1mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O2">
            <title>ARM A 3mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O3">
            <title>Arm A 10mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O4">
            <title>Arm B 1mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O5">
            <title>Arm B 3mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O6">
            <title>Arm B 10mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet (PLT) Nadir</title>
          <description>Blood counts were performed at least two times a week and when clinically indicated during the study and daily when PLT count is &lt; 50K/μL until recovery (two consecutive counts showing upward trend). The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
          <units>K/μL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="3.0"/>
                    <measurement group_id="O2" value="26.3" spread="11.1"/>
                    <measurement group_id="O3" value="24.8" spread="13.0"/>
                    <measurement group_id="O4" value="22.5" spread="8.9"/>
                    <measurement group_id="O5" value="18.3" spread="6.3"/>
                    <measurement group_id="O6" value="8" spread="2.2"/>
                    <measurement group_id="O7" value="11.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days Platelets Count of &lt; 100K/μL</title>
        <description>The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
        <time_frame>Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A 1mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O2">
            <title>Arm A 3mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O3">
            <title>Arm A 10mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O4">
            <title>Arm B 1mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O5">
            <title>Arm B 3mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O6">
            <title>Arm B 10mcg/kg</title>
            <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by either 1 mcg/kg or 3 mcg/kg or 10 mcg/kg AMG531 subcutaneously on days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy Cycle 1, Chemotherapy (R-HyperCVAD) alone. Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B) R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Platelets Count of &lt; 100K/μL</title>
          <description>The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir &lt; 25K/μL) in the absence of platelet transfusion in the blinded study cycle.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.9"/>
                    <measurement group_id="O2" value="5.3" spread="1.1"/>
                    <measurement group_id="O3" value="8.3" spread="2.3"/>
                    <measurement group_id="O4" value="6.8" spread="1.7"/>
                    <measurement group_id="O5" value="8" spread="0.8"/>
                    <measurement group_id="O6" value="9.3" spread="2.0"/>
                    <measurement group_id="O7" value="9.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Toxicity assessments with each dose level/cycle (3 week cycle) up to 6 cycles; overall study treatment period four years and three months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E2">
          <title>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E3">
          <title>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Arm A &amp; Arm B) With Chemotherapy</title>
          <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy&#xD;
Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E5">
          <title>1 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E6">
          <title>3 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
        <group group_id="E7">
          <title>10 mcg/ kg AMG531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.&#xD;
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)&#xD;
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan-Raj, MD/Professor, Sarcoma Medical Oncology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7966</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

